

Supporting Information

DNAzyme Adsorbed Polydopamine@MnO₂ Core-Shell

Nanocomposites for Enhanced Photothermal Therapy via Self- Activable Suppression of Heat Shock Protein 70

Yang Xi¹, Xin Xie², Ying Peng¹, Peng Liu¹, Jinsong Ding*¹ and Wenhui Zhou*^{1,3}

¹. Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, 410013, China

². School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China

³. Academician Workstation, Changsha Medical University, Changsha 410219, China

*Email:

zhouwenhuyaoji@163.com




Figure S1. Dynamic size change of PDA@MnO₂/DZ during 7 days storage. No macroscopic aggregate and precipitate were observed after 7 days storage in different media at room temperature, indicating the high stability of PDA@MnO₂/DZ. Inset: Appearance of the nanoparticles after 7 days storage in different media.




Figure S2. Adsorption kinetics of FAM labeled-DZ (100 nM) on PDA@MnO₂ NPs (200 µg/mL).




Figure S3. (A) Size distribution and (B) ζ -potential of PDA@MnO₂ and PDA@MnO₂/DZ nanoparticles.




Figure S4. Temperature increase curves of different samples under 808 nm irradiation (2 W/cm²) for 500 s.




Figure S5. Probing the intracellular Mn²⁺ release using 2,7-dichlorodihydrofluorescein

(DCFH-DA) after different treatments. Scare bar: 200 μm .




Figure S6. (A) Flow cytometry analysis the uptake of free DZ and PDA@MnO₂/DZ by M231 cells, and (B) the quantified fluorescence intensity.




Figure S7. Hemolysis assay of PDA@MnO₂/DZ at various concentrations. PBS and ultrapure water were used as the negative and positive control, respectively. Inset: Appearance of different treatments after centrifugation.




Figure S8. (A) The dynamic body weight of M231 tumor-bearing mice during different treatments.




Figure S9. Hematoxylin and eosin (H&E) staining images of the major organs after different treatments. Scale bar: 200 μm . The treatments were as follows: (1) PBS, (2) PDA@MnO₂, (3) PDA@MnO₂/DZ, (4) PDA@MnO₂ + Laser, (5) PDA@MnO₂/DZ + Laser.




Figure S10. Evaluation of the (A) hepatotoxicity (B) and nephrotoxicity of different treatments by measuring the serum levels of ALT, AST, BUN and Cre. The treatments were as follows: (1) PBS, (2) PDA@MnO₂, (3) PDA@MnO₂/DZ, (4) PDA@MnO₂ + Laser, (5) PDA@MnO₂/DZ + Laser.